Skip to main content
Erschienen in: Pediatric Cardiology 8/2011

01.12.2011 | Original Article

Prediction of the Risk of Coronary Arterial Lesions in Kawasaki Disease by Brain Natriuretic Peptide

verfasst von: Kazunari Kaneko, Ken Yoshimura, Atsushi Ohashi, Takahisa Kimata, Tomohiko Shimo, Shoji Tsuji

Erschienen in: Pediatric Cardiology | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Kawasaki disease (KD) is an acute systemic vasculitis associated with the development of coronary arterial lesions (CALs) occurring in 3–5% of children treated by intravenous immune globulin (IVIG). However, a considerable number of patients who are not responding to IVIG are at much higher risk. Although studies have explored potential biomarkers to predict patients with KD who are at risk of CAL, no useful single marker exists. We hypothesized that the serum concentrations of the N-terminal moiety of brain natriuretic peptide (NT-proBNP) can be useful to predict CAL. Forty-three children with KD (29 males and 14 females) were enrolled in this study. Despite IVIG, 6 of the 43 patients developed CAL. There were, however, no significant differences in variables between children with CAL and those without CAL: These include age, gender, day of the illness, leukocyte count, and the serum levels of sodium, C-reactive protein, and albumin. The serum NT-proBNP level was significantly higher in children with CAL than those without CAL (2,611 ± 1,699 vs. 1,073 ± 1,427 pg/ml; P = 0.03): the cutoff value of 1,000 pg/ml to predict CAL produced a specificity of 0.68, sensitivity of 0.83, and an odds ratio as high as 10.4. In conclusion, NT-proBNP is increased in KD patients who are developing CAL, and patients with an elevated serum NT-proBNP >1,000 pg/ml have a risk of CAL ~10 times higher than that of patients with a modest increase.
Literatur
1.
Zurück zum Zitat Albers S, Mir TS, Haddad M, Läer S (2006) N-terminal pro brain natriuretic peptide: evaluation of pediatric reference values including method comparison and interlaboratory variability. Clin Chem Lab Med 44:80–85PubMedCrossRef Albers S, Mir TS, Haddad M, Läer S (2006) N-terminal pro brain natriuretic peptide: evaluation of pediatric reference values including method comparison and interlaboratory variability. Clin Chem Lab Med 44:80–85PubMedCrossRef
2.
Zurück zum Zitat Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW (1998) A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 81:1116–1120PubMedCrossRef Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW (1998) A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 81:1116–1120PubMedCrossRef
5.
Zurück zum Zitat Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, Spiegelblatt L, Bonny Y, Vartian M, Montigny M (2009) Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 30:810–817PubMedCrossRef Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, Spiegelblatt L, Bonny Y, Vartian M, Montigny M (2009) Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 30:810–817PubMedCrossRef
6.
Zurück zum Zitat Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24:145–148PubMedCrossRef Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24:145–148PubMedCrossRef
7.
Zurück zum Zitat Japan Kawasaki Disease Research Committee (1984) Diagnostic guidelines of Kawasaki disease. 4th rev. ed. Japan Kawasaki Disease Committee, Tokyo Japan Kawasaki Disease Research Committee (1984) Diagnostic guidelines of Kawasaki disease. 4th rev. ed. Japan Kawasaki Disease Committee, Tokyo
8.
Zurück zum Zitat Kawamura T, Wago M (2002) Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young 12:153–158PubMedCrossRef Kawamura T, Wago M (2002) Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young 12:153–158PubMedCrossRef
9.
Zurück zum Zitat Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M (2000) Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 42:241–248PubMedCrossRef Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M (2000) Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 42:241–248PubMedCrossRef
10.
Zurück zum Zitat Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113:2606–2612PubMedCrossRef Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113:2606–2612PubMedCrossRef
11.
Zurück zum Zitat Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H (2009) Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J 28:498–502PubMedCrossRef Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H (2009) Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J 28:498–502PubMedCrossRef
12.
Zurück zum Zitat Kurotobi S, Kawakami N, Shimizu K, Aoki H, Nasuno S, Takahashi K, Kogaki S, Ozono K (2005) Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 26:425–430PubMedCrossRef Kurotobi S, Kawakami N, Shimizu K, Aoki H, Nasuno S, Takahashi K, Kogaki S, Ozono K (2005) Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 26:425–430PubMedCrossRef
13.
Zurück zum Zitat Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K (1993) Increased serum levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82–91PubMed Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K (1993) Increased serum levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82–91PubMed
14.
Zurück zum Zitat Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, Shirakami G, Jougasaki M, Imura H (1990) Human brain natriuretic peptide, a novel cardiac hormone. Lancet 335:801–802PubMedCrossRef Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, Shirakami G, Jougasaki M, Imura H (1990) Human brain natriuretic peptide, a novel cardiac hormone. Lancet 335:801–802PubMedCrossRef
15.
Zurück zum Zitat Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T (2006) Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95:189–193PubMedCrossRef Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T (2006) Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95:189–193PubMedCrossRef
16.
Zurück zum Zitat Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, Ojima T, Sonobe T, Yanagawa H (2004) Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 46:33–38PubMedCrossRef Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, Ojima T, Sonobe T, Yanagawa H (2004) Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 46:33–38PubMedCrossRef
17.
Zurück zum Zitat Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K, Son C, Lee J (2009) Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 168:1315–1321PubMedCrossRef Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K, Son C, Lee J (2009) Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 168:1315–1321PubMedCrossRef
18.
19.
Zurück zum Zitat Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195–203PubMed Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195–203PubMed
Metadaten
Titel
Prediction of the Risk of Coronary Arterial Lesions in Kawasaki Disease by Brain Natriuretic Peptide
verfasst von
Kazunari Kaneko
Ken Yoshimura
Atsushi Ohashi
Takahisa Kimata
Tomohiko Shimo
Shoji Tsuji
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 8/2011
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-011-9986-8

Weitere Artikel der Ausgabe 8/2011

Pediatric Cardiology 8/2011 Zur Ausgabe

Images in Pediatric Cardiology

Cardiac Lymphangioma in an Infant

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.